Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | FPR2 | P25090 | 11/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8088674 | 0.85 | FPR2 (0.56) | FOLH1FPR2 | |
| SCHEMBL4600137 | 0.84 | FOLH1 (0.63) | FOLH1FPR2CA1CA2 | |
| SCHEMBL4600141 | 0.84 | FOLH1 (0.63) | FOLH1FPR2CA1CA2 | |
| SCHEMBL7448276 | 0.84 | CA12 (0.53) | FPR2ALDH1A1CA12CA1CA2 | |
| SCHEMBL7448273 | 0.84 | CA12 (0.53) | FPR2ALDH1A1CA12CA1CA2 | |
| SCHEMBL6375538 | 0.81 | FPR2 (0.75) | FOLH1FPR2ALDH1A1 | |
| SCHEMBL6375530 | 0.81 | FPR2 (0.75) | FOLH1FPR2ALDH1A1 | |
| SCHEMBL6376189 | 0.81 | FPR2 (0.75) | FOLH1FPR2ALDH1A1 | |
| SCHEMBL14948910 | 0.79 | FOLH1 (0.61) | FOLH1FPR2ALDH1A1CA1CA2 | |
| SCHEMBL21141315 | 0.74 | RAB9A (0.56) | ALDH1A1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051625-A1 | ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES | Du Pont Pharmaceuticals Company (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999038014-A1 | ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |